Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.8.0.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2018
Equity [Abstract]  
Schedule of the allocation of stock-based compensation

The stock-based compensation expense attributable to option grants was allocated as follows:

 

    Three months ended March 31,  
    2018     2017  
Cost of product sales   $ 50     $  
Research and development cost     112       87  
General and administrative expense     (18 )     74  
Total   $ 144     $ 161  
Schedule of assumptions used in the black-scholes-Merton option-pricing model

The following assumptions were used in the Black-Scholes-Merton pricing model to estimate the fair value of options granted during the periods presented.

 

  Three months ended March 31,
  2018   2017
       
Expected stock volatility 78.4%-79.9%   70.9%-72.2%
Risk free interest rate 2.06%-2.45%   1.53%-1.79%
Expected years until exercise 3.5   3.5
Dividend yield 0%   0%